

## REFERENCES

1. Blake J. Menopause: evidence-based practice. *Best Pract Res Clin Obstet Gynaecol* 2006;20(6):799-839.
2. Beck W. *Obstetrics and Gynecology*. National medical series for independent study. Philadelphia Harwal Publishing 1993:359-60.
3. Bennett R, Brown L. *Myles Textbook for Midwives*. Edinburgh: Churchill Livingstone 1996;37.
4. Davison S, Davis SR. Hormone replacement therapy: current controversies. *Clin Endocrinol* 2003;58(3):249-61.
5. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. *Obstet Gynecol* 1995;85(2):304-13.
6. Hickey M, Davis SR, Sturdee DW. Treatment of menopausal symptoms: what shall we do now? *Lancet* 2005;366(9483):409-21.
7. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. *Ann Intern Med* 2002;137(10):805-13.
8. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, et al. Effect of estrogen plus progestin on stroke in postmenopausal women. *JAMA* 2003;289(20):2675-8.
9. Writing group for the women's health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal

results from the women's health initiative randomized controlled trial. *JAMA* 2002;288(3):321-33.

10. Setchell KD. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. *Am J Clin Nutr* 1998;68(6):1333S-46S.
11. Zhang X, Shu XO, Gao YT, Yang G, Li Q, Li H, Jin F, Zheng W. Soy food consumption is associated with lower risk of coronary heart disease in chinese women. *J Nutr* 2003;133(9):2874-8.
12. Alekel DL, Germain AS, Peterson CT, Hanson KB, Stewart JW, Toda T. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. *Am J Clin Nutr* 2000;72(3):844-52.
13. Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW Jr. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. *Am J Clin Nutr* 1998;68(6 Suppl):1375S-9S.
14. Wu AH, Wan P, Hankin J, Tseng CC, Yu MC, Pike MC. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. *Carcinogenesis* 2002;23(9):1491-6.
15. Cross HS, Kállay E, Lechner D, Gerdenitsch W, Adlercreutz H, Armbrecht HJ. Phytoestrogens and vitamin D metabolism: a new concept for the prevention and therapy of colorectal, prostate, and mammary carcinomas. *J Nutr* 2004;134(5):1207S-12S.
16. Philp HA. Hot flashes - a review of the literature on alternative and complementary treatment approaches. *Altern Med Re* 2003;8(3):284-302.

17. Ye YB, Tang XY, Verbruggen MA, Su YX. Soy isoflavones attenuate bone loss in early postmenopausal Chinese women: a single-blind randomized, placebo-controlled trial. *Eur J Nutr* 2006;45(6):327-34.
18. Uesugi T, Fukui Y, Yamori Y. Beneficial effects of soybean isoflavone supplementation on bone metabolism and serum lipids in postmenopausal Japanese women: a four week study. *J Am Coll Nutr* 2002;21(2):97-102.
19. Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. *J Am Coll Nutr* 2003;22(2):142-6.
20. Holick MF. High prevalence of vitamin D inadequacy and implications for health. *Mayo Clin Proc* 2006;81(3):353-73.
21. Suda T, Takahashi N, Abe E. Role of vitamin D in bone resorption. *J Cell Biochem* 1992;49(1):53-8.
22. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. *JAMA* 2005;293(18):2257-64.
23. Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. *J Pharmacol Exp Ther* 2001;299(3):849-57.
24. Jemnitz K, Lengyel G, Vereczkey L. In vitro induction of bilirubin conjugation in primary rat hepatocyte culture. *Biochem Biophys Res Commun* 2002;291(1):29-33.

25. Soars MG, Petullo DM, Eckstein JA, Kasper SC, Wrighton SA. An assessment of UDP-glucuronosyltransferase induction using primary human hepatocytes. *Drug Metab Dispos* 2004;32(1):140-8.
26. Bock KW, Lilienblum W, von Bahr C. Studies of UDP-glucuronyltransferase activities in human liver microsomes. *Drug Metab Dispos* 1984;12(1):93-7.
27. Park JY, Kim KA, Kim SL. Chloramphenicol is a potent inhibitor of cytochrome p450 isoforms CYP2C19 and CYP3A4 in human liver microsomes. *Antimicrob Agents Ch* 2003;47(11):3464-9.
28. Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. *Antimicrob Agents Ch* 2001;45(2):382-92.
29. Piskula MK, Yamakoshi J, Iwai Y. Daidzein and genistein but not their glucosides are absorbed from the rat stomach. *FEBS Lett* 1999;447(2-3):287-91.
30. Setchell KD. Absorption and metabolism of soy isoflavones - from food to dietary supplements and adults to infants. *J Nutr* 2000;130(3):654S-5S.
31. Kenneth DR, Cassidy A. Dietary isoflavones: biological effects and relevance to human health. *J Nutr* 1999;129(3):758S-67S.
32. Miksicek RJ. Interaction of naturally occurring nonsteroidal estrogens with expressed recombinant human estrogen receptor. *J Steroid Biochem Mol Biol* 1994;49(2-3):153-60.
33. Markiewicz L, Garey J, Adlercreutz H, Gurbide E. In vitro bioassays of nonsteroidal phytoestrogens. *J Steroid Biochem Mol Biol* 1993;45(5):399-405.

34. Routledge EJ, White R, Parker MG, Sumpter JP. Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ERbeta. *J Biol Chem* 2000;275(46):35986-93.
35. Kurzer MS, Xu X. Dietary phytoestrogens. *Ann Rev Nutr* 1997;17:353-81.
36. Reinli K, Block G. Phytoestrogen content of foods - a compendium of literature values. *Nutr Cancer* 1996;26(2):123-48.
37. Wang H, Murphy PA. Isoflavone content in commercial soybean foods. *J Agric Food Chem* 1994;42(8):1666-73.
38. Barnes S, Kirk M, Coward L. Isoflavones and their conjugates in soy foods: extraction conditions and analysis by HPLC-mass spectrometry. *J Agric Food Chem* 1994;42(11):2466-74.
39. Adlercreutz H, Fotsis T, Bannwart C, Wähälä K, Mäkelä T, Brunow G, Hase T. Determination of urinary lignans and phytoestrogen metabolites, potential antiestrogens and anticarcinogens, in urine of women on various habitual diets. *J Steroid Biochem Mol Biol* 1986;25(5B):791-7.
40. King RA, Bursill DB. Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans. *Am J Clin Nutr* 1998;67(5):867-72.
41. Xu X, Wang HJ, Murphy PA, Hendrich S. Bioavailability of soybean isoflavones depends upon gut microflora in women. *J Nutr* 1995;125(9):2307-15.
42. Xu X, Murphy PA, Cook L, Hendrich S. Daidzein is a more bioavailable soy milk isoflavone than is genistein in adult women. *J Nutr* 1994;124(6):825-32.

43. Brown JP. Hydrolysis of glycosides and esters. In: role of the gut flora in toxicity and cancer. Rowland, I.R, ed. Academic Press Inc, San Diego, CA 1988:109-44.
44. Setchell KD, Brown NM, Desai PB, Zimmer-Nechimias L, Wolfe B, Jakate AS, Creutzinger V, Heubi JE. Bioavailability, disposition, and dose-response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes. *J Nutr* 2003;133(4):1027-35.
45. Daya AJ, DuPont MS, Ridley S, Rhodes M, Rhodes MJ, Morgan MR, Williamson G. Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver beta-glucosidase activity. *FEBS Lett* 1998;436(1):71-5.
46. Schmitt E, Dekant W, Stopper H. Assaying the estrogenicity of phytoestrogens in cells of different estrogen sensitive tissues. *Toxicol In Vitro* 2001;15:433-9.
47. Heinonen S, Wähälä K, Adlercreutz H. Identification of isoflavone metabolites dihydrodaidzein, dihydrogenistein, 6-OH-O-dma, and cis-4-OH-equol in human urine by gas chromatography-mass spectroscopy using authentic reference compounds. *Anal Biochem* 1999;274(2):211-9.
48. Kelly GE, Nelson C, Waring MA, Joannou GE, Reeder AY. Metabolites of dietary soya isoflavones in human urine. *Clin Chim Acta* 1993;223(1-2):9-22.
49. Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. *J Nutr* 2002;132(12):3577-84.

50. Joannou GE, Kelly GE, Reeder AY, Waring M, Nelson C. A urinary profile study of dietary phytoestrogens. The identification and mode of metabolism of new isoflavonoids. *J Steroid Biochem Mol Biol* 1995;54(3):167-84.
51. Kelly GE, Joannou GE, Reeder AY, Nelson C, Waring MA. The variable metabolic response to dietary isoflavones in humans. *Exp Biol Med* 1995;208(1):40-3.
52. Rowland I, Wiseman H, Sander T, Adlercreutz H, Bowey E. Metabolism of estrogens and phytoestrogens: role of the gut microflora. *Biochem Soc Trans* 1999;27(2):304-8.
53. Tang BY, Adams NR. Effect of equol on estrogen receptors and on synthesis of DNA and protein I the immature rat uterus. *J Endocrinol* 1980;85(2):291-7.
54. Coward L, Kirk M, Albin N, Barnes S. Analysis of plasma isoflavones by reversed-phase HPLC multiple reaction ion monitoring-mass spectrometry. *Clin Chim Acta* 1996;247:121-42.
55. Birt DF, Hendrich S, Wang W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. *Pharmacol Ther* 2001;90(2-3):157-77.
56. Setchell KD, Brown NM, Desai P, Zimmer-Nechemias L, Wolfe BE, Brashear WT, Kirschner AS, Cassidy A, Heubi JE. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. *J Nutr* 2001;131(4 Suppl):1362S-75.
57. Lu LJ, Anderson KE. Sex and long-term soy diets affect the metabolism and excretion of soy isoflavones in humans. *Am J Clin Nutr* 1998;68(6):1500S-4S.

58. Zheng Y, Hu J, Murphy PA, Alekel DL, Franke WD, Hendrich S. Rapid gut transit time and slow fecal isoflavone disappearance phenotype are associated with greater genistein bioavailability in women. *J Nutr* 2003;133(10):3110-6.
59. Setchell KD, Borriello SP, Hulme P, Kirk DN, Axelson M. Nonsteroidal estrogens of dietary origin: possible roles in hormonedependent disease. *Am J Clin Nutr* 1984;40(3):569-78.
60. Setchell KD, Zimmer-Nechemias L, Cai J, Heubi JE. Exposure of infants to phyto-oestrogens from soy-based infant formula. *Lancet* 1997;350(9070):23-7.
61. Setchell KD, Faughnan MS, Avades T, Zimmer-Nechemias L, Brown NM, et al. Comparing the pharmacokinetics of daidzein and genistein with the use of <sup>13</sup>C-labeled tracers in premenopausal women. *Am J Clin Nutr* 2003;77(2):411-9.
62. Zhang Y, Hendrich S, Murphy PA. Glucuronides are the main isoflavone metabolites in women. *J Nutr* 2003;133(2):399-404.
63. Tew BY, Xu X, Wang HJ, Murphy PA, Hendrich S. A diet high in wheat fiber decreases the bioavailability of soybean isoflavones in a single meal fed to women. *J Nutr* 1996;126(4):871-7.
64. Adlercreutz H HH, Higashi A, Fotsis T, Hämäläinen E, Hasegawa T, Okada H. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. *Am J Clin Nutr* 1991;54(6):1093-100.
65. de Pascual-Teresa S, Hallund J, Talbot D, Schroot J, Williams CM, Bugel S, Cassidy A. Absorption of isoflavones in humans: effects of food matrix and processing. *J Nutr Biochem* 2006;17(4):257-64.

66. Faughnan MS, Hawdon A, Ah-Singh E, Brown J, Millward DJ, Cassidy A. Urinary isoflavone kinetics: the effect of age, gender, food matrix and chemical composition. *Br J Nutr* 2004;91(4):567-74.
67. Xu X, Wang HJ, Murphy PA, Hendrich S. Neither background diet nor type of soy food affects short-term isoflavone bioavailability in women. *J Nutr* 2000;130(4):798-801.
68. Hutchins AM. Urinary isoflavonoid phytoestrogen and lignan excretion after consumption of fermented and unfermented soy products. *J Am Diet Assoc* 1995;95(5):545-51.
69. Lee SJ, Ahn JK, Kim SH, Kim JT, Han SJ, Jung MY, Chung IM. Variation in isoflavone of soybean cultivars with location and storage duration. *J Agric Food Chem* 2003;51(11):3382-9.
70. Eisen Bi, Ungar Y, Shimoni E. Stability of isoflavones in soy milk stored at elevated and ambient temperatures. *J Agric Food Chem* 2003;51(8):2212-5.
71. Xu Z, Wu Q, Godber JS. Stabilities of daidzin, glycitin, genistin, and generation of derivatives during heating. *J Agric Food Chem* 2002;50(25):7402-6.
72. Mahungu SM, Diaz-Mercado S, Li J, Schwenk M, Singletary K, Faller J. Stability of isoflavones during extrusion processing of corn/soy mixture. *J Agric Food Chem* 1999;47(1):279-84.
73. Li D, Park JH, Park JT, Park CS, Park KH. Biotechnological production of highly soluble daidzein glycosides using *Thermotoga maritima* maltosyltransferase. *J Agric Food Chem* 2004;52(9):2561-7.

74. Zhang Y, Wang GJ, Song TT, Murphy PA, Hendrich S. Urinary disposition of the soybean isoflavones daidzein, genistein and glycitein differs among humans with moderate fecal isoflavone degradation activity. *J Nutr* 2001;291(5):957-62.
75. Shelnutt SR, Cimino CO, Wiggins PA, Ronis MJ, Badger TM. Pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage. *Am J Clin Nutr* 2002;76(3):588-94.
76. Lampe JW, Karr SC, Hutchins AM, Slavin JL. Urinary equol excretion with a soy challenge: influence of habitual diet. *Proc Soc Exp Biol Med* 1998;217(3):335-9.
77. Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, Chambon P. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. *Nature* 1986;320:134-9.
78. Kuiper GG. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. *Proc Natl Acad Sci USA* 1996;93(12):5925-30.
79. Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. *Endocrinology* 1997;138(3):863-70.
80. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. *Endocrinology* 1998;139(10):4252-63.

81. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/ antagonists. *Mol Pharmacol* 1998;54(1):105-12.
82. An J, Tzagarakis-Foster C, Scharschmidt TC, Lomri N, Leitman DC. Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens. *J Biol Chem* 2001;276(21):17808-14.
83. Morito K. Interaction of phytoestrogens with estrogen receptors alpha and beta. *Biol Pharm Bull* 2001;24(4):351-6.
84. Liu J, Knappenberger KS, Kack H, Andersson G, Nilsson E, Dartsch C, Scott CW. A homogeneous in vitro functional assay for estrogen receptors: coactivator recruitment. *Mol Endocrinology* 2003;17(3):346-55.
85. Muthyala RS, Ju YH, Sheng S, Williams LD, Doerge DR, Katzenellenbogen BS, Helferich WG, Katzenellenbogen JA. Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta. *Bioorg Med Chem* 2004;12(6):1559-67.
86. Mueller SO, Simon S, Chae K, Metzler M, Korach KS. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptoralpha (ERalpha) and ERbeta in human cells. *Toxicol Sci* 2004;80(1):14-25.
87. Kurebayashi S, Miyashita Y, Hirose T, Kasayama S, Akira S, Kishimoto T. Characterization of mechanisms of interleukin 6 gene repression by estrogen receptor. *J Steroid Biochem Mol Biol* 1997;60(1-2):11-7.

88. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. *Science* 1997;277(5331):1508-10.
89. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P. Estrogen receptor pathways to AP-1. *Steroid Biochem Mol Biol* 2000;74(5):311-7.
90. Wu JJ, Geimonen E, Andersen J. Increased expression of estrogen receptor beta in human uterine smooth muscle at term. *J Eur J Endocrinol* 2000;142(1):92-9.
91. Maruyama S, Fujimoto N, Asano K, Ito A. Suppression by estrogen receptor beta of AP-1 mediated transactivation through estrogen receptor alpha. *J Steroid Biochem* 2001;78(2):177-84.
92. Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, Price RH Jr, Pestell RG, Kushner PJ. Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. *J Biol Chem* 2002;277(27):24353-60.
93. Kanda N, Watanabe S. 17Beta-estradiol inhibits MCP-1 production in human keratinocytes. *J Invest Dermatol* 2003;120(6):1058-66.
94. Pelletier G, El-Alfy M. Immunocytochemical localization of estrogen receptors alpha and beta in the human reproductive organs. *J Clin Endocrinol Metab* 2000;85(12):4835-40.
95. Palmieri C, Saji S, Sakaguchi H, Cheng G, Sunter A, O'Hare MJ, Warner M, Gustafsson JA, Coombes RC, Lam EW. The expression of oestrogen receptor (ER)-beta and its variants, but not ERalpha, in adult human mammary fibroblasts. *J Mol Endocrinol* 2004;33:35-50.

96. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? *Endocr Rev* 1999;20(3):358-417.
97. Gustafsson JA, Warner M. Estrogen receptor beta in the breast: role in estrogen responsiveness and development of breast cancer. *J Steroid Biochem Mol Biol* 2000;74(5):245-8.
98. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. *Cancer Res* 2004;64(1):423-8.
99. Dotzlaw H, Leygue E, Watson PH, Murphy LC. Expression of estrogen receptor-beta in human breast tumors. *J Clin Endocrinol Metab* 1997;82(7):2371-4.
100. Fuqua SA, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, Clark GM, Allred DC. Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. *Cancer Res* 2003;63(10):2434-9.
101. Murrill WB, Brown NM, Zhang JX, Manzolillo PA, Barnes S, Lamartiniere CA. Prepubertal genistein exposure suppresses mammary cancer and enhances gland differentiation in rats. *Carcinogenesis* 1996;17(16):1451-7.
102. Lamartiniere CA, Murrill WB, Manzolillo PA, Zhang JX, Barnes S, Zhang X, Wei H, Brown NM. Genistein alters the ontogeny of mammary gland development and protects against chemically-induced mammary cancer in rats. *Proc Soc Exp Biol Med* 1998;217(3):358-64.
103. Cabanes A, Wang M, Olivo S, DeAssis S, Gustafsson JA, Khan G, Hilakivi-Clarke L. Prepubertal estradiol and genistein exposures up-regulate BRCA1 mRNA and reduce mammary tumorigenesis. *Carcinogenesis* 2004;25(5):741-8.

104. Jin Z, MacDonald RS. Soy isoflavones increase latency of spontaneous mammary tumors in mice. *J Nutr* 2002;132(10):3186-90.
105. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptorpositive human breast cancer (MCF-7) cells in vitro and in vivo. *Cancer Res* 1998;58(17):3833-8.
106. Allred CD, Allred KF, Ju YH, Virant SM, Helferich WG. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dosedependent manner. *Cancer Res* 2001;61(13):5045-50.
107. Ju YH, Allred CD, Allred KF, Karko KL, Doerge DR, Helferich WG. Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen- dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. *J Nutr* 2001;131(11):2957-62.
108. Young HJ, Doerge DR, Allred KF, Allred CD, Helferich WG. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. *Cancer Res* 2002;62(9):2474-7.
109. Allred CD, Allred KF, Ju YH, Clausen LM, Doerge DR, Schantz SL, Korol DL, Wallig MA, Helferich WG. Dietary genistein results in larger MNU induced, estrogen-dependent mammary tumors following ovariectomy of Sprague-Dawley rats. *Carcinogenesis* 2004;25(2):211-8.
110. Duncan AM, Underhill KE, Xu X, Lavalleur J, Phipps WR, Kurzer MS. Modest hormonal effects of soy isoflavones in postmenopausal women. *J Clin Endocrinol Metab* 1999;84(10):3479-84.

111. Kurzer MS. Hormonal effects of soy in premenopausal women and men. *J Nutr* 2002;132(3):570S-3S.
112. Balk JL, Whiteside DA, Naus G, DeFerrari E, Roberts JM. A pilot study of the effects of phytoestrogen supplementation on postmenopausal endometrium. *J Soc Gynecol Investig* 2002;9(4):238-42.
113. Penotti M, Fabio E, Modena AB, Rinaldi M, Omodei U, Viganó P. Effect of soy-derived isoflavones on hot flushes, endometrial thickness, and the pulsatility index of the uterine and cerebral arteries. *Fertil Steril* 2003;79(5):1112-7.
114. Sammartino A, Di Carlo C, Mandato VD, Bifulco G, Di Stefano M, Nappi C. Effects of genistein on the endometrium: ultrasonographic evaluation. *Gynecol Endocrinol* 2003;17(1):45-9.
115. Murray MJ, Meyer WR, Lessey BA, Oi RH, DeWire RE, Fritz MA. Soy protein isolate with isoflavones does not prevent estradiol-induced endometrial hyperplasia in postmenopausal women: a pilot trial. *Menopause* 2003;10(5):456-64.
116. Santell RC, Chang YC, Nair MG, Helferich WG. Dietary genistein exerts estrogenic effects upon the uterus, mammary gland and the hypothalamic/pituitary axis in rats. *J Nutr* 1997;127(2):263-9.
117. Taylor AH, Al-azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues. *J Mol Endocrinol* 2000;24(1):145-55.
118. Vehkavaara S, Silveira A, Hakala-Ala-Pietilä T, Virkamäki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Järvinen H. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis,

inflammation and serum lipids and lipoproteins in postmenopausal women. *Thromb Haemost* 2001;85(4):619-25.

119. Hemelaar M, van der Mooren MJ, Mijatovic V, Bouman AA, Schijf CP, Kroeks MV, Franke HR, Kenemans P. Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein (a) in postmenopausal women: a randomized, placebo-controlled study. *Menopause* 2003;10(6):550-8.
120. Nanda S, Gupta N, Mehta HC, Sangwan K. Effect of oestrogen replacement therapy on serum lipid profile. *Aust N Z J Obstet Gynaecol* 2003;43(3):213-6.
121. Schunkert H, Danser AH, Hense HW, Derkx FH, Kürzinger S, Riegger GA. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. *Circulation* 1997;95(1):39-45.
122. Helle SI, OmsjØ IH, Hughes SC, Botta L, Hüls G, Holly JM, Lønning PE. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. *Clin Endocrinol (Oxf)* 1996;45(6):727-32.
123. Paasilta M, Karjalainen A, Kervinen K, Savolainen MJ, Heikkinen J, Bäckström AC, Kesäniemi YA. Insulin-like growth factor binding protein-1 (IGFBP-1) and IGF-I during oral and transdermal estrogen replacement therapy: relation to lipoprotein(a) levels. *Atherosclerosis* 2000;149(1):157-62.
124. Cardim HJ, Lopes CM, Giannella-Neto D, da Fonseca AM, Pinotti JA. The insulin-like growth factor-I system and hormone replacement therapy. *Fertil Steril* 2001;75(2):282-7.

125. Biglia N, Ambroggio S, Ponzone R, Sgro L, Ujcic E, Dato FA, Sismondi P. Modification of serum IGF-I, IGFbps and SHBG levels by different HRT regimens. *Maturitas* 2003;45(4):283-91.
126. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/ progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. *Arterioscler Thromb Vasc Biol* 1997;17(11):3071-8.
127. Lowe GD, Upton MN, Rumley A, McConnachie A, O'Reilly DS, Watt GC. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein-a cross-sectional population survey. *Thromb Haemost* 2001;86(2):550-6.
128. Lowe GD. Hormone replacement therapy: prothrombotic vs. protective effects. *Pathophysiol Haemost Thromb* 2002;32(5-6):329-32.
129. Post MS, Christella M, Thomassen LG, van der Mooren MJ, van Baal WM, Rosing J, Kenemans P, Stehouwer CD. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. *Arterioscler Thromb Vasc Biol* 2003;23(6):1116-21.
130. Oger E, Alhenc-Gelas M, Lacut K, Blouch MT, Roudaut N, Kerlan V, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. *Arterioscler Thromb Vasc Biol* 2003;23(9):1671-6.

131. Greaves KA, Parks JS, Williams JK, Wagner JD. Intact dietary soy protein, but not adding an isoflavone-rich soy extract to casein, improves plasma lipids in ovariectomized cynomolgus monkeys. *J Nutr* 1999;129(8):1585-92.
132. Lichtenstein AH, Jalbert SM, Adlercreutz H, Goldin BR, Rasmussen H, Schaefer EJ, Ausman LM. Lipoprotein response to diets high in soy or animal protein with and without isoflavones in moderately hypercholesterolemic subjects. *Arterioscler Thromb Vasc Biol* 2002;22(11):1852-8.
133. Weggemans RM, Trautwein EA. Relation between soy-associated isoflavones and LDL and HDL cholesterol concentrations in humans: a meta-analysis. *Eur J Clin Nutr* 2003;57:940-6.
134. Demonty I, Lamarche B, Jones PJ. Role of isoflavones in the hypocholesterolemic effect of soy. *Nutr Rev* 2003;61(6):189-203.
135. Adams KF, Newton KM, Chen C, Emerson SS, Potter JD, White E, Lampe JW. Soy isoflavones do not modulate circulating insulin-like growth factor concentrations in an older population in an intervention trial. *J Nutr* 2002;133(5):1316-9.
136. Teede HJ, Dalais FS, McGrath BP. Dietary soy containing phytoestrogens does not have detectable estrogenic effects on hepatic protein synthesis in postmenopausal women. *Am J Clin Nutr* 2004;79(3):396-401.
137. Shah SH, Alexander KP. Hormone replacement therapy for primary and secondary prevention of heart disease. *Curr Treat Options Cardiovasc Med* 2003;5(1):25-33.

138. Evans MJ, Harris HA, Miller CP, Karathanasis SK, Adelman SJ. Estrogen receptors alpha and beta have similar activities in multiple endothelial cell pathways. *Endocrinology* 2002;143(10):3785-95.
139. Chambliss KL, Shaul P. Estrogen modulation of endothelial nitric oxide synthase. *Endocr Rev* 2002;23(5):665-86.
140. McNeill AM, Kim N, Duckles SP, Krause DN, Kontos HA. Chronic estrogen treatment increases levels of endothelial nitric oxide synthase protein in rat cerebral microvessels. *Stroke* 1999;30(10):2186-90.
141. Yang S, Bae L, Zhang L. Estrogen increases eNOS and NOx release in human coronary artery endothelium. *J Cardiovasc Pharmacol* 2000;36(2):242-7.
142. Stirone C, Chu Y, Sunday L, Duckles SP, Krause DN. 17 Beta-estradiol increases endothelial nitric oxide synthase mRNA copy number in cerebral blood vessels: quantification by real-time polymerase chain reaction. *Eur J Pharmacol* 2003;478(1):35-8.
143. Haynes MP, Li L, Sinha D, Russell KS, Hisamoto K, Baron R, et al. Src kinase mediates phosphatidylinositol 3- kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen. *J Biol Chem* 2003;278(4):2118-23.
144. Chambliss KL, Yuhanna IS, Anderson RG, Mendelsohn ME, Shaul PW. ERbeta has nongenomic action in caveolae. *Mol Endocrinology* 2002;16(5):938-46.
145. Wagner AH, Schroeter MR, Hecker M. 17Beta-estradiol inhibition of NADPH oxidase expression in human endothelial cells. *FASEB J* 2001;15(12):2121-30.

146. Rubanyi GM, Freay AD, Kauser K, Sukovich D, Burton G, Lubahn DB, et al. Vascular estrogen receptors and endothelium- derived nitric oxide production in the mouse aorta. *J Clin Invest* 1997;99(10):2429-37.
147. Tan E, Gurjar MV, Sharma RV, Bhalla RC. Estrogen receptor-alpha gene transfer into bovine aortic endothelial cells induces eNOS gene expression and inhibits cell migration. *Cardiovasc Res* 1999;43(3):788-97.
148. Geary GG, McNeill AM, Ospina JA, Krause DN, Korach KS, Duckles SP. Selected contribution: cerebrovascular nos and cyclooxygenase are unaffected by estrogen in mice lacking estrogen receptor-alpha. *J Appl Physiol* 2001;91(5):2391-9.
149. Rubanyi GM, Kauser K, Johns A. Role of estrogen receptors in the vascular system. *Vascul Pharmacol* 2002;38(2):81-8.
150. Darblade B, Pendaries C, Krust A, Dupont S, Fouque MJ, Rami J, et al. Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor. *Circ Res* 2002;90(4):413-9.
151. Widder J, Pelzer T, von Poser-Klein C, Hu K, Jazbutyte V, Fritzemeier KH, et al. Improvement of endothelial dysfunction by selective estrogen receptor-alpha stimulation in ovariectomized SHR. *Hypertension* 2003;42(5):991-6.
152. Muller-Delp JM, Lubahn DB, Nichol KE, Philips BJ, Price EM, Curran EM, Laughlin MH. Regulation of nitric oxide-dependent vasodilation in coronary arteries of estrogen receptor- alpha-deficient mice. *Am J Physiol Heart Circ Physiol* 2003;285(5):H2150-7.
153. Nuedling S, Karas RH, Mendelsohn ME, Katzenellenbogen JA, Katzenellenbogen BS, Meyer R, Vetter H, Grohé C. Activation of estrogen

receptor beta is a prerequisite for estrogen-dependent upregulation of nitric oxide synthases in neonatal rat cardiac myocytes. *FEBS Lett* 2001;502(3):103-8.

154. Kakui K, Itoh H, Sagawa N, Yura S, Korita D, Takemura M, et al. Augmented endothelial nitric oxide synthase (eNOS) protein expression in human pregnant myometrium: possible involvement of eNOS promoter activation by estrogen via both estrogen receptor (ER)alpha and ERbeta. *Mol Hum Reprod* 2004;10(2):115-22.
155. Zhu Y, Bian Z, Lu P, Karas RH, Bao L, Cox D, et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. *Science* 2002;295(5554):505-8.
156. Mäkelä S, Savolainen H, Aavik E, Myllärniemi M, Strauss L, Taskinen E, Gustafsson JA, Häyry P. Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors alpha and beta. *Proc Natl Acad Sci USA* 1999;96(12):7077-82.
157. Squadrito F, Altavilla D, Morabito N, Crisafulli A, D'Anna R, Corrado F, et al. The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women. *Atherosclerosis* 2002;163(2):339-47.
158. Squadrito F, Altavilla D, Crisafulli A, Saitta A, Cucinotta D, Morabito N, et al. Effect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study. *Am J Med* 2003;114(6):470-6.
159. Lissin LW. Isoflavones improves vascular reactivity in post-menopausal women with hypercholesterolemia. *Vasc Med* 2004;9(1):26-30.

160. Walker HA, Dean TS, Sanders TA, Jackson G, Ritter JM, Chowienczyk PJ. The phytoestrogen genistein produces acute nitric oxide-dependent dilation of human forearm vasculature with similar potency to 17beta-estradiol. *Circulation* 2001;103(2):258-62.
161. Teede HJ, Dalais FS, Kotsopoulos D, Liang YL, Davis S, McGrath BP. Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women. *J Clin Endocrinol Metab* 2001;86(97):3053-60.
162. McCrohon JA, Walters WA, Robinson JT, McCredie RJ, Turner L, Adams MR, Handelsman DJ, Celermajer DS. Arterial reactivity is enhanced in genetic males taking high dose estrogen. *J Am Coll Cardiol* 1997;2(7):1432-6.
163. New G, Duffy SJ, Harper RW, Meredith IT. Long-term oestrogen therapy is associated with improved endothelium- dependent vasodilation in the forearm resistance circulation of biological males. *Clin Exp Pharmacol Physiol* 2000;27(1-2):25-33.
164. Sader MA, McCredie RJ, Griffiths KA, Wishart SM, Handelsman DJ, Celermajer DS. Oestradiol improves arterial endothelial function in healthy men receiving testosterone. *Clin Endocrinol (Oxf)* 2001;54(2):175-81.
165. Hanke H, Hanke S, Ickrath O, Lange K, Bruck B, Mück AO, et al. Estradiol concentrations in premenopausal women with coronary heart disease. *Coron Artery Dis* 1997;8(8-9):511-5.
166. Christian RC, Harrington S, Edwards WD, Oberg AL, Fitzpatrick LA. Estrogen status correlates with the calcium content of coronary atherosclerotic plaques in women. *J Clin Endocrinol Metab* 2002;87(3):1062-7.

167. Bairey Merz CN, Johnson BD, Sharaf BL, Bittner V, Berga SL, Braunstein GD, et al. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. *J Am Coll Cardiol* 2003;41(3):413-9.
168. Koka S, Petro TM, Reinhardt RA. Estrogen inhibits interleukin-1beta-induced interleukin-6 production by human osteoblast-like cells. *J Interferon Cytokine Res* 1998;18(7):479-83.
169. Bord S, Ireland DC, Beavan SR, Compston JE. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. *Bone* 2003;32(2):136-41.
170. Chen X, Garner SC, Quarles LD, Anderson JJ. Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. *J Nutr Biochem* 2003;14(6):342-9.
171. Viereck V, Gründker C, Blaschke S, Siggelkow H, Emons G, Hofbauer LC. Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. *J Cell Biochem*. 2002;84:725-35.
172. Aguirre J, Buttery L, O'Shaughnessy M, Afzal F, Fernandez de Marticorena I, et al. Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity. *Am J Pathol* 2001;158 (1):247-57.
173. Samuels A, Perry MJ, Gibson RL, Colley S, Tobias JH. Role of endothelial nitric oxide synthase in estrogen-induced osteogenesis. *Bone* 2001;29(1):24-9.

174. McFarlane SI, Muniyappa R, Shin JJ, Bahtiyar G, Sowers JR. Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? *Endocrine* 2004;23(1):1-10.
175. Potier M, Karl M, Zheng F, Elliot SJ, Striker GE, Striker LJ. Estrogen-related abnormalities in glomerulosclerosis-prone mice: reduced mesangial cell estrogen receptor expression and pro-sclerotic response to estrogens. *Am J Pathol* 2002;160:1877-85.
176. Potier M, Elliot SJ, Tack I, Lenz O, Striker GE, Striker LJ, Karl M. Expression and regulation of estrogen receptors in mesangial cells: influence on matrix metalloproteinase-9. *J Am Soc Nephrol* 2001;12(2):241-51.
177. Lei J, Silbiger S, Ziyadeh FN, Neugarten J. Serum-stimulated alpha 1 type IV collagen gene transcription is mediated by TGF-beta and inhibited by estradiol. *Am J Physiol Heart Circ Physiol* 1998;274(2 Pt 2):F252-8.
178. Silbiger S, Lei J, Ziyadeh FN, Neugarten J. Estradiol reverses TGF-beta1-stimulated type IV collagen gene transcription in murine mesangial cells. *Am J Physiol Heart Circ Physiol* 1998;274(6 Pt 2):F1113-8.
179. Craven PA, Studer RK, Felder J, Phillips S, DeRubertis FR. Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells. *Diabetes* 1997;46(4):671-81.
180. Velasquez MT, Bhatena SJ. Dietary phytoestrogens: a possible role in renal disease protection. *Am J Kidney Dis* 2001;37(5):1056-68.
181. Ranich T, Bhatena SJ, Velasquez MT. Protective effects of dietary phytoestrogens in chronic renal disease. *J Ren Nutr Cancer* 2001;11(4):183-93.

182. Morabito N, Crisafulli A, Vergara C, Gaudio A, Lasco A, Frisina N, et al. Effects of genistein and hormonereplacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. *J Bone Miner Res* 2002;17(10):1904-12.
183. Yamori Y, Moriguchi EH, Teramoto T, Miura A, Fukui Y, Honda KI, et al. Soy, isoflavones, and breast cancer risk in Japan. *J Natl Cancer Inst* 2003;95(12):906-13.
184. Chen YM, Ho SC, Lam SS, Ho SS, Woo JL. Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial. *J Clin Endocrinol Metab* 2003;88(10):4740-7.
185. Chen YM, Ho SC, Lam SS, Ho SS, Woo JL. Beneficial effect of soy isoflavones on bone mineral content was modified by years since menopause, body weight, and calcium intake: a double-blind, randomized, controlled trial. *Menopause* 2004;11(3):246-54.
186. Crisafulli A, Altavilla D, Squadrito G, Romeo A, Adamo EB, Marini R, et al. Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women. *J Clin Endocrinol Metab* 2004;89(1):188-92.
187. Hsu CS, Shen WW, Hsueh YM, Yeh SL. Soy isoflavone supplementation in postmenopausal women. Effects on plasma lipids, antioxidant enzyme activities and bone density. *J Reprod Med* 2001;46(10):221-6.
188. Gallagher JC, Satpathy R, Rafferty K, Haynatzka V. The effect of soy protein isolate on bone metabolism. *Menopause* 2004;11(3):290-8.

189. Kreijkamp-Kaspers S, Kok L, Grobbee DE, de Haan EH, Aleman A, Lampe JW, van der Schouw YT. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. *JAMA* 2004;292(1):65-74.
190. Somekawa Y, Chiguchi M, Ishibashi T, Aso T. Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. *Obstet Gynecol* 2001;97(1):109-15.
191. Ho SC, Woo J, Lam S, Chen Y, Sham A, Lau J. Soy protein consumption and bone mass in early postmenopausal Chinese women. *Osteoporos Int* 2003;14(10):835-42.
192. Kardinaal AF, Morton MS, Brüggemann-Rotgans IE, van Beresteijn EC. Phyto-oestrogen excretion and rate of bone loss in postmenopausal women. *Eur J Clin Nutr* 1998;52(11):850-5.
193. Kim MK, Chung BC, Yu VY, Nam JH, Lee HC, Huh KB, Lim SK. Relationships of urinary phyto-oestrogen excretion to BMD in postmenopausal women. *Clin Endocrinol (Oxf)* 2002;56(3):321-8.
194. Nagata C, Shimizu H, Takami R, Hayashi M, Takeda N, Yasuda K. Soy product intake and serum isoflavonoid and estradiol concentrations in relation to bone mineral density in postmenopausal Japanese women. *Osteoporos Int* 2002;13(3):200-4.
195. Kritz-Silverstein D, Goodman-Gruen DL. Usual dietary isoflavone intake, bone mineral density, and bone metabolism in postmenopausal women. *J Womens Health Gend Based Med* 2002;11(1):69-78.

196. McCarty MF. Coping with endothelial superoxide: potential complementarity of arginine and high-dose folate. *Med Hypotheses* 2004;63(4):709-18.
197. Boger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. *Cardiovasc Res* 2003;59(4):824-33.
198. Vidal O, Kindblom LG, Ohlsson C. Expression and localization of estrogen receptor-beta in murine and human bone. *J Bone Miner Res* 1999;14(6):923-9.
199. Bord S, Horner A, Beavan S, Compston J. Estrogen receptors alpha and beta are differentially expressed in developing human bone. *J Clin Endocrinol Metab* 2001;86(5):2309-14.
200. Meeker DR, Kesten H.D. Effects of high protein diets on experimental atherosclerosis of rabbits. *Arch pathol* 1941;31:147-62.
201. Clarkson R, Anthony MS, Williams JK, Honoré EK, Cline JM. The potential of soybean phytoestrogens for postmenopausal hormone replacement therapy. *Proc Soc Exp Biol Med* 1998;128:209-13.
202. Goodman-Gruen D, Kritz-Silverstein D. Usual dietary isoflavone intake is associated with cardiovascular disease risk factors in postmenopausal women. *J Nutr* 2001;131:1202-06.
203. Anderson J, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. *N Engl J Med* 1995;333(5):276-82.
204. Wangen K, Duncan AM, Xu X, Kurzer MS. Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic postmenopausal women. *Am J Clin Nutr* 2001;73:235-41.
205. Crouse J, JR 3rd, Morgan T, Terry JG, Ellis J, Vitolins M, Burke GL.

- A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. *Arch Int med* 1999;159 (17):2070-6.
206. Washburn S, Burke GL, Morgan T, Anthony M. Effect of soy protein supplementation on serum lipoproteins, blood pressure and menopausal symptoms in perimenopausal women. *Menopause* 1999;6(1):7-13.
207. Howes JB, Sullivan D, Lain N, Estel P, Pomeroy S, West L, Eden JA, Howes LG. The effects of dietary supplementation with isoflavones from red clover on lipoprotein profiles of post menopausal women with mild to moderate hypercholesterolemia. *Atherosclerosis* 2000;152(1):143-7.
208. Baum J, Teng H; Erdman JW, Weigel M, Klein BP, Persky VW, et al. Long-term intake of soy protein improves blood lipid profiles and increase mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women. *Am J Clin Nutr* 1998;68 :545-51.
209. Potter SM. Overview of proposed mechanisms of the hypocholesterolemic effect of soy. *J Nutr* 1995;125(3 Suppl):606S-11S.
210. Silbiger SR, Neugarten J. The impact of gender on the progression of chronic renal disease. *Am J Kidney Dis* 1995;25(4):515-33.
211. Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. *J Am Soc Nephrol* 2000;11(12) :319-29.
212. Neugarten J, Gallo G, Silbiger S, Kasiske B. Glomerulosclerosis in aging humans is not influenced by gender. *Am J Kidney Dis* 1999;34(5):884-8.

213. Sakemi T, Toyoshima H, Shouno Y, Morito F. Estrogen attenuates progressive glomerular injury in hypercholesterolemic male Imai rats. *Nephron* 1995;69(2):159-65.
214. Sakemi T, Ohtsuka N, Tomiyoshi Y, Morito F. Testosterone does not eliminate the attenuating effect of estrogen on progressive glomerular injury in estrogen-treated hypercholesterolemic male Imai rats. *Kidney Blood Press Res* 1997;20(1):51-6.
215. Xiao S, Gillespie DG, Baylis C, Jackson EK, Dubey RK. Effects of estradiol and its metabolites on glomerular endothelial nitric oxide synthesis and mesangial cell growth. *Hypertension* 2001;37(2 Part 2):645-50.
216. Elliot SJ, Karl M, Berho M, Potier M, Zheng F, Leclercq B, Striker GE, Striker LJ. Estrogen deficiency accelerates progression of glomerulosclerosis in susceptible mice. *Am J Pathol* 2003;162(5):1441-8.
217. Antus B, Hamar P, Kokeny G, Szollosi Z, Mucsi I, Nemes Z, Rosivall L. Estradiol is nephroprotective in the rat remnant kidney. *Nephrol Dial Transplant* 2003;18(1):54-61.
218. Gross ML, Adamczak M, Rabe T, Harbi NA, Krtil J, Koch A, Hamar P, Amann K, Ritz E. Beneficial effects of estrogens on indices of renal damage in uninephrectomized SHRsp rats. *J Am Soc Nephrol Dial Transplant* 2004;15(2):348-58.
219. Maric C, Sandberg K, Hinojosa-Laborde C. Glomerulosclerosis and tubulointerstitial fibrosis are attenuated with 17beta-estradiol in the aging Dahl salt sensitive rat. *J Am Soc Nephrol* 2004;15(6):1546-56.

220. Studer RK, Craven PA, DeRubertis FR. Antioxidant inhibition of protein kinase C-signaled increases in transforming growth factor-beta in mesangial cells. *Metabolism* 1997;46(8):918-25.
221. Toyoda M, Suzuki D, Honma M, Uehara G, Sakai T, Umezono T, Sakai H. High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy. *Kidney Int* 2004;66(3):1107-14.
222. Weigert C, Sauer U, Brodbeck K, Pfeiffer A, Häring HU, Schleicher ED. AP-1 proteins mediate hyperglycemia-induced activation of the human TGF-beta1 promoter in mesangial cells. *J Am Soc Nephrol* 2000;11(11):2007-16.
223. Singh LP, Green K, Alexander M, Bassly S, Crook ED. Hexosamines and TGF-beta1 use similar signaling pathways to mediate matrix protein synthesis in mesangial cells. *Am J Physiol Renal Physiol* 2004;286(2):F409-16.
224. Weiss RH, Ramirez A. TGF-beta- and angiotensin-II-induced mesangial matrix protein secretion is mediated by protein kinase C. *Nephrol Dial Transplant* 1998;13(11):2804-13.
225. Singh R, Song RH, Alavi N, Pegoraro AA, Singh AK, Leehey DJ. High glucose decreases matrix metalloproteinase-2 activity in rat mesangial cells via transforming growth factor-beta1. *Exp Nephrol* 2001;9(4):249-57.
226. Poncelet AC, Schnaper HW. Regulation of human mesangial cell collagen expression by transforming growth factor-beta1. *Am J Physiol Renal Physiol* 1998;275(3 Pt 2):F458-66.
227. Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Böttinger EP,

- Klotman PE, Thorgeirsson SS. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. *Lab Invest* 1996;74(6):991-1003.
228. Ali SM, Laping NJ, Fredrickson TA, Contino LC, Olson B, Anderson K, Brooks DP. Angiotensin-converting enzyme inhibition attenuates proteinuria and renal TGF-beta 1 mRNA expression in rats with chronic renal disease. *Pharmacology* 1998;57(1):20-7.
229. Sharma R, Khanna A, Sharma M, Savin VJ. Transforming growth factor-beta1 increases albumin permeability of isolated rat glomeruli via hydroxyl radicals. *Kidney Int* 2000;58(1):131-6.
230. Fujimoto M, Maezawa Y, Yokote K, Joh K, Kobayashi K, Kawamura H, et al. Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. *Biochem Biophys Res Commun* 2003;305(4):1002-7.
231. Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M, et al. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. *J Am Soc Nephrol* 2003;14(7):1816-24.
232. Sakemi T, Ikeda Y, Shimazu K, Uesugi T. Attenuating effect of a semipurified alcohol extract of soy protein on glomerular injury in spontaneous hypercholesterolemic male Imai rats. *Am J Kidney Dis* 2001;37(4):832-7.
233. Matsuda T, Yamamoto T, Muraguchi A, Saatcioglu F. Crosstalk between transforming growth factor-beta and estrogen receptor signaling through Smad3. *J Biol Chem* 2001;276(46):42908-14.
234. Slater M, Brown D, Husband A. In the prostatic epithelium, dietary isoflavones from red clover significantly increase estrogen receptor beta and E-cadherin

expression but decrease transforming growth factor beta1. Prostate Cancer Prostatic Dis 2002;5(1):16-21.

235. Lim WK, Wren B, Jepson N, Roy S, Caplan G. Effect of hormone replacement therapy on left ventricular hypertrophy. Am J Cardiol 1999;83(7):1132-4. A9.
236. du Cailar G, Ribstein J, Pasquié JL, Mimran A. Determinant of left ventricular hypertrophy in the hypertensive woman. Influence of hormone replacement therapy for menopause. Arch Mal Coeur Vaiss 1999;92:975-7.
237. Modena MG, Molinari R, Muia N Jr, Castelli A, Pala F, Rossi R. Double-blind randomized placebo-controlled study of transdermal estrogen replacement therapy on hypertensive postmenopausal women. Am J Hypertens 1999;12(10 Pt 1):1000-8.
238. Modena MG, Muia N Jr, Aveta P, Molinari R, Rossi R. Effects of transdermal 17beta-estradiol on left ventricular anatomy and performance in hypertensive women. Hypertension 1999;34(5):1041-6.
239. McCarty MF. Adjuvant strategies for prevention of glomerulosclerosis. Med Hypotheses 2006;67(6):1277-96.
240. Higuchi Y, Otsu K, Nishida K, Hirotsu S, Nakayama H, Yamaguchi O, et al. The small GTP-binding protein Rac1 induces cardiac myocyte hypertrophy through the activation of apoptosis signal-regulating kinase 1 and nuclear factor-kappa B. J Biol Chem 2003;278(23):20770-7.
241. Simko F, Simko J. The potential role of nitric oxide in the hypertrophic growth of the left ventricle. Physiol Res. 2000;49(1):37-46.

242. Grohé C, Kahlert S, Löbber K, Stimpel M, Karas RH, Vetter H, Neyses L. Cardiac myocytes and fibroblasts contain functional estrogen receptors. *FEBS Lett* 1997;416(1):107-12.
243. Signoretti S, Loda M. Estrogen receptor beta in prostate cancer: brake pedal or accelerator? *Am J Pathol* 2001;159(1):13-6.
244. Ho SM. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. *J Cell Biochem* 2004;91(3):491-503.
245. Royuela M, de Miguel MP, Bethencourt FR, Sánchez-Chapado M, Fraile B, Arenas MI, Paniagua R. Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. *J Endocrinol* 2001;168(3):447-54.
246. Fixemer T, Remberger K, Bonkhoff H. Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. *Prostate Cancer Prostatic Dis* 2003;54(2):79-87.
247. Kregge JH, Hodgins JB, Couse JF, Enmark E, Warner M, Mahler JF, et al. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. *Proc Natl Acad Sci USA* 1998;95(26):15677-82.
248. Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, Webster JI, et al. A role for estrogen receptor beta in the regulation of growth of the ventral prostate. *Proc Natl Acad Sci USA* 2001;98(11):6330-5.
249. Bektic J, Berger AP, Pfeil K, Dobler G, Bartsch G, Klocker H. Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein

- in androgen-dependent LNCaP cells is mediated by estrogen receptor beta. *Eur Urol* 2004;45(2):245-51.
250. Fritz WA, Wang J, Eltoum IE, Lamartiniere CA. Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate. *Mol Cell Endocrinol* 2002;186(1):89-99.
251. Hussain M, Banerjee M, Sarkar FH, Djuric Z, Pollak MN, Doerge D, et al. Soy isoflavones in the treatment of prostate cancer. *Nutr Cancer* 2003;47(2):111-7.
252. deVere White RW, Hackman RM, Soares SE, Beckett LA, Li Y, Sun B. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. *Urology* 2004;63(2):259-63.
253. Messina MJ. Emerging evidence on the role of soy in reducing prostate cancer risk. *Nutr Rev* 2003;61(4):117-31.
254. Ozaſa K, Nakao M, Watanabe Y, Hayashi K, Miki T, Mikami K, et al. Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. *Cancer Sci* 2004;95(1):65-71.
255. McCarty MF. Isoflavones made simple-genistein's agonist activity for the beta-type estrogen receptor mediates their health benefits. *Med Hypotheses* 2006;66(6):1093-14.
256. Sandy J, Davies M, Prime S, Farndale R. Signal pathways that transduce growth factor-stimulated mitogenesis in bone cells. *Bone* 1998;23(1):17-26.
257. Nakanishi H, Yamanouchi K, Gotoh Y, Nagayama M. The association of platelet-derived growth factor (PDGF) receptor tyrosine phosphorylation to mitogenic response of human osteoblastic cells in vitro. *Oral Dis* 1997;3(1):36-242.

258. Shutt DA. The effects of plant oestrogens on animal reproduction. *Endeavour* 1976;35(126):110-3.
259. Whitten PL, Lewis C, Russell E, Naftolin F. Phytoestrogen influences on the development of behavior and gonadotropin function. *Proc Soc Exp Biol Med* 1995;208(1):82-6.
260. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D<sub>3</sub>: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D<sub>3</sub> synthesis in human skin. *J Clin Endocrinol Metab* 1988;67(2):373-8.
261. Clemens TL, Adams JS, Henderson SL, Holick MF. Increased skin pigment reduces the capacity of the skin to synthesize vitamin D. *Lancet* 1982;1:74-6.
262. Need AG, Morris HA, Horowitz M, Nordin C. Effects of skin thickness, age, body fat and sunlight on serum 25-hydroxyvitamin D. *Am J Clin Nutr* 1993;58(6):882-5.
263. Feldman D, Pike JW, Glorieux FH, Editors. *Vitamin D* (2<sup>th</sup> edition). Elsevier Academic Press London, San Diego 2005.
264. Lips P. Vitamin D physiology. *Prog Biophys Mol Biol* 2006;92(1):4-8.
265. Avenell A, Gillespie WJ, Gillespie LD, O'Connell DL. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. *Cochrane Database Syst Rev* 2005;(3):CD000227.
266. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ. Vitamin D<sub>3</sub> and calcium to prevent hip fractures in the elderly women. *N Engl J Med* 1992;327(23):1637-42.

267. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. *N Engl J Med* 1997;337(10):670-76.
268. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al. Calcium plus vitamin D supplementation and the risk of fractures. *N Engl J Med* 2006;354(7):669-83.
269. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, Wong JB. Effect of vitamin D on falls: a meta-analysis. *JAMA* 2004;291(16):1999-2006.
270. Speroff L, Fritz M. *Clinical gynecologic endocrinology and infertility* (6<sup>th</sup> edition). Baltimore : Lippincott Williams & Wilkins 1999:643-780.
271. Thomas BF, Zeisel SH, Busby MG, Hill JM, Mitchell RA, et al. Quantitative analysis of the principle soy isoflavones genistein, daidzein and glycitein, and their primary conjugated metabolites in human plasma and urine using reversedphase high-performance liquid chromatography with ultraviolet detection. *J Chromatography B* 2001;760(2):191-205.
272. Mcleod H. Pharmacokinetics for the Prescriber. *Medicine* 2003;31(8):11-5.
273. Watanabe S, Yamaguchi M, Sobue T, Takahashi T, Miura T, Arai Y, Mazur W, Wähälä K, Adlercreutz H. Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako). *J Nutr* 1998;128:1710-5.
274. Vergne S, Bernard V, Asselineau J, Durand M, Lamothe V, Potier M, et al. Bioavailability and urinary excretion of isoflavones in humans: effects of soy-

- based supplements formulation and equol production. *Pharm Biomed Anal* 2007;43(4):1488-94.
275. Rowland I, Faughnan M, Hoey L, Wahala K, Williamson G, Cassidy A. Bioavailability of phytoestrogens. *Br J Nutr* 2003;89 (Suppl 1):S45-S58.
276. Parodi P. The role of intestinal bacteria in the causation and prevention of cancer: modulation by diet and probiotics. *Aust J Dairy Tech* 1999;54:103-21.
277. Anupongsanugool E, Teekachunhatean S, Rojanasthien N, Pongsatha S, Sangdee C. Pharmacokinetics of isoflavones, daidzein and genistein, after ingestion of soy beverage compared with soy extract capsules in postmenopausal Thai women. *BMC Clin Pharmacol* 2005;5(1):2.
278. Foti P, Erba D, Spadafranca A, Ciappellano S, Bresciana J, Testolin G. Daidzein is absorbed by passive transport in isolated small intestine of rats. *Nutr Res* 2006;26:284-8.
279. Straub DA. Calcium supplementation in clinical practice: a review of forms, doses, and indications. *Nutr Clin Pract* 2007;22:286-96.
280. Setchell KD, Cassidy A. Dietary isoflavones: biological effects and relevance to human health. *J Nutr* 1999;129:758S-67S.